Lundbeck
PharmaCopenhagen, Denmark, Denmark · Est. 1915 · 8,200 employees
Lundbeck is a Danish pharmaceutical company focused on developing and commercializing innovative treatments for psychiatric and neurological disorders.
2
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
15
Indications↗
Distinct diseases across all programs
235
Clinical Trials↗
All sponsored trials (all statuses)
6
Orange Book Patents
Across 2 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
2 drugs in development
Phase 32
Phase 21
Phase 11
By Therapeutic Area
top 6
Neurology
225%
Psychiatry
113%
Musculoskeletal
113%
Cardiovascular
113%
Ophthalmology
113%
Metabolic & Endocrine
113%
R&D Momentum
44/100
Pipeline Velocity
0/100
Trial Completion Rate
81/100
Pipeline Concentration
16/100
Pipeline Freshness
72/100
Strategic Signals
- ↗Active in Neurology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Earlier
Mar 18, 2026TrialPROMISE-3: Eptinezumab in Medication-Overuse Headache
Mar 9, 2026TrialSPARX-3: Safinamide Add-On in Early PD
May 10, 2025TrialDELIVER: Eptinezumab in Chronic Migraine
Dec 18, 2024TrialA Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
Dec 3, 2024TrialA Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
Sep 19, 2024TrialA Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease
Sep 13, 2024TrialA Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
4 more events
Jun 19, 2024TrialA Trial of Lu AG13909 in Adult Participants With Cushing's Disease
Jun 17, 2024FDASabril — VIGAFYDE
Apr 10, 2024TrialA Study Investigating the Movement of Lu AF28996 Into, Through, and Out of the Body of Healthy Men
Apr 1, 2024TrialA Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
Details
Company Info
Company Overview
$9.5B
Mkt Cap
$2.2B
Revenue
—
Cash
CEODeborah Dunsire
Founded1915
Employees8,200
HQCopenhagen, Denmark, Denmark
Websitelundbeck.com
LinkedInCompany Page
Therapeutic Focus
psychiatryneurologypain managementaddiction
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular
Musculoskeletal
Neurology
Ophthalmology
Psychiatry
Unknown / Other
Cardiovascular
Ischemic Stroke
Lu AF95245Phase 1
Musculoskeletal
Fibromyalgia
Lu AF95245Phase 1
Neurology
Ataxia
Lu AF95245Phase 2
Epilepsy
Lu AF95245Phase 1
Migraine
Lu AF95245Phase 2
Multiple Sclerosis
Lu AF95245Phase 1
Multiple System Atrophy
AmlenetugPhase 3
Lu AF95245Phase 2
Ophthalmology
Psychiatry
Unknown / Other
Headache
Lu AF95245Phase 1
Showing 15 of 16 programs
Regulatory
Regulatory Timeline
19841 event
FDAMay 14
Winstrol — WINSTROL
Application NDA012885 (NDA)
20092 events
FDAAug 21
Sabril — SABRIL
Application NDA022006 (NDA)
FDAAug 21
Sabril — SABRIL
Application NDA020427 (NDA)
20111 event
FDAOct 21
Sympazan — ONFI
Application NDA202067 (NDA)
20121 event
FDADec 14
Sympazan — ONFI
Application NDA203993 (NDA)
20141 event
FDAFeb 18
Northera — NORTHERA
Application NDA203202 (NDA)
20181 event
FDANov 1
Sympazan — SYMPAZAN
Application NDA210833 (NDA)
20201 event
FDAFeb 21
Vyepti — VYEPTI
Application BLA761119 (BLA)
20241 event
FDAJun 17
Sabril — VIGAFYDE
Application NDA217684 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)